Core Insights - Virbac achieved a strong 7.9% organic growth in 2025, reflecting the strength of its portfolio and operational model [1][5] - The companion animal segment drove performance with a notable 10.9% growth, supported by the launch of innovative products like Vikaly [2][5] - Strategic acquisitions, such as Thyronorm, are expected to enhance the company's offerings and contribute to future growth [3][11] Financial Performance - Full-year 2025 revenue reached €1,465 million, marking a 4.8% increase at actual rates and 7.9% at constant exchange rates and scope [5][8] - Q1 revenue was €375 million, Q2 was €363 million, Q3 was €364 million, and Q4 was €362 million, with Q4 showing a 7.1% growth at constant exchange rates [6][10] - Adjusted recurring operating income is projected to be around 17% for 2026, with revenue growth guidance set between 5.5% and 7.5% at constant rates and scope [16] Geographic Performance - North America saw a significant growth of 14.7% at constant exchange rates, driven by successful product launches and strong existing product performance [9][11] - Europe experienced a growth of 9.8% at constant exchange rates, primarily due to the farm animal segment's response to the bluetongue virus epidemic [9][11] - The IMEA region recorded a robust increase of 12.6% at constant exchange rates, led by strong performance in both farm and companion animal segments [9][11] Strategic Initiatives - The acquisition of Thyronorm, a product for treating feline hyperthyroidism, is expected to enhance Virbac's portfolio and contribute to revenue growth [11][12] - The company continues to focus on research and development investments to advance animal health solutions [3][11] - Virbac's strategy includes transitioning distribution in Europe from partners to direct management, enhancing control over its product offerings [12]

The broader medical and health products industry continues to evolve under the dual pressures of regulatory oversight and the need for differentiated, clinically validated solutions. Across pharmaceuticals, nutritional supplements and animal health, companies are increasingly focusing on niche markets, specialty products and science-backed innovation rather than broad commoditized offerings.Recent industry trends underscore a growing emphasis on targeted therapies and specialty products for clearly defined ...

Core Viewpoint - Zomedica Corp. is enhancing its digital capabilities and long-term innovation strategy, as highlighted in its upcoming investor webinar scheduled for January 23, 2026 [1] Group 1 - Zomedica is an animal health company focused on innovative diagnostic and therapeutic devices for equine and companion animals [1] - The company will host the next session of its "Fourth Friday at Four" investor webinar series on January 23, 2026, at 4:00 p.m. Eastern Time [1]

Core Insights - Elanco Animal Health is undergoing significant transformation, presenting a consistent growth trajectory driven by historical innovation [3] Group 1: Company Overview - Elanco held an Investor Day in December, focusing on strategy, historical pipeline, financial profile, and executive team [2] - The company is described as being fundamentally different compared to five years ago, indicating substantial progress and development [3] Group 2: Financial and Strategic Focus - The presentation highlighted a solid and consistent flow of growth stemming from the company's historical innovations [3]

Elanco Conference Call Summary Company Overview - **Company**: Elanco Animal Health - **Industry**: Animal Health - **Current Status**: Elanco is experiencing a mid-single-digit growth rate, with nine consecutive quarters of growth across both farm and pet segments [3][5] Core Insights and Arguments Financial Performance - Elanco is guiding for $840 million to $880 million in innovation revenue by 2025, with a commitment to grow this to $1.1 billion by 2026 [4] - The company aims for high single-digit EBITDA growth and low double-digit EPS growth starting this year [5] - Elanco expects to generate approximately $1 billion in cash flow over the next three years and aims to reduce leverage to under three times by 2027 [5][32] Innovation and Product Pipeline - Elanco has launched six blockbusters since 2021, with a pipeline valued at $2 billion across eight therapeutic areas [4][29] - The company is committed to introducing five to six additional blockbusters by the end of the decade [4][29] - Credelio Quattro is highlighted as a significant product, expected to become the largest in the company's history, with a market share of about 30% in the U.S. [22][39] Market Trends - The pet health market is valued at $17 billion and is growing faster than the farm segment, with high single-digit growth predicted [8] - Key trends driving growth include increased spending by pet owners, the rise of omnichannel shopping, and the globalization of pet ownership [9][11] - The farm animal segment, while growing slower, is considered more durable and is expected to grow at mid-single digits [50] Competitive Landscape - Elanco operates in a high-barrier industry with strong brand loyalty among veterinarians and pet owners, which mitigates risks associated with patent cliffs [6][7] - The company is positioned as a leader in both pet retail and farm animal health, with a focus on innovation and comprehensive product portfolios [15][16] Additional Important Insights - Elanco Ascend is a company-wide initiative aimed at driving productivity and cost savings, with a focus on operations and procurement [52][53] - The company is experiencing a shift in pricing strategy, expecting to implement the highest price increases in five years based on the value provided to customers [38][47] - Elanco's strategy includes a balanced approach to capital allocation, focusing on organic investments, debt reduction, and potential small M&A opportunities [55] Conclusion Elanco is positioned for sustainable growth through innovation, a strong product pipeline, and strategic market positioning. The company is focused on enhancing its financial profile while navigating industry trends and competitive dynamics.

Financial Performance and Outlook - Elanco expects organic constant currency revenue growth starting in 2025[10] - The company anticipates adjusted EBITDA growth starting in 2026[10] - Elanco projects over $1 billion in total free cash flow from 2026 to 2028[10] - The company aims to reduce net leverage to below 3x in 2027 and further towards 20x-25x[10] - Elanco expects innovation to deliver $11 billion in revenue in 2026, compared to $840-$880 million in 2025[90] Innovation and Pipeline - Elanco's innovation engine is expected to generate $840-$880 million in revenue in 2025[34] - The "Big 6" products are projected to drive $11 billion in innovation revenue in 2026[39] - The company anticipates 5-6 potential blockbuster approvals between 2026 and 2031, with peak sales exceeding $2 billion[10, 61, 90] - Elanco's "Next Wave" innovation portfolio includes over 15 projects across 8 innovation spaces[58, 59] Market and Industry Trends - The animal health industry is projected to grow from $42 billion to $60 billion[11] - The pet health industry is a $17 billion market experiencing mid-single-digit to high-single-digit growth[16] - The farm animal health industry is a $25 billion market with low-single-digit to mid-single-digit growth[17] Elanco Ascend and Cost Savings - Elanco Ascend is expected to generate approximately $200-$250 million in adjusted EBITDA savings by 2030, net of inflation and reinvestment[71, 90] - The company anticipates approximately $25 million in savings in 2026, $60 million in 2027, and $130 million in cash cost[90]

PresentationGood morning, everybody. I'm Chris Schott from JPMorgan. It's my pleasure to be introducing Zoetis today. From the company, we have a presentation from CEO, Kristin Peck, and we'll have Wetteny Joseph, company's CFO, available for Q&A. So with that, Kristin, happy New Year and looking forward to the presentation.Kristin PeckCEO & Director Well, thank you, Chris, and welcome to everyone. It is great to be back at JPMorgan, and I'm excited to share today how Zoetis is defining the next era in anim ...

44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Leading the Future of Animal Health January 12, 2026 Forward-Looking Statements This presentation contains forward-looking statements, which reflect the current views of Zoetis with respect to: industry growth and market outlook; business plans or prospects; future operating or financial performance; future guidance; future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under developm ...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20258 390 660Gross total of voting rights : 12 704 596Net total* of voting ri ...

ImmuCell estimates the worldwide total addressable market for scour protection at approximately $900 million. The company’s stated strategy is to increase customer engagement using “strong medical, scientific, and outcomes-based arguments” to drive adoption.Management pointed to changes in the economics of newborn calves as a key driver for increased demand for scour protection. Taboukos said calf values have risen substantially over the past five years, citing factors including beef-on-dairy cross-breeding ...